Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
New JPMA Task Force to Respond to ICH-GL and PMD Act Amendments
The Japan Pharmaceutical Manufacturers Association (JPMA) plans to set up a new task force in FY2025 to propel the establishment of a clinical trial ecosystem in Japan and address evolving regulations based on ICH guidelines and proposed legal amendments. The…
To read the full story
Related Article
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
April 3, 2025
ORGANIZATION
- PhRMA Sues CMS over Medicare MFN Model, Calls It Unlawful Overreach
October 9, 2026
- Japan Generic Group Calls for Clearer Patent Extension Rules
October 9, 2026
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
- JPMA Chief Urges Manufacturing, Talent Push to Build Drug Discovery Ecosystem
October 8, 2026
- PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…